Epigenetics in cancer stem cells

Tan Boon Toh 1, Jhin Jieh Lim 1 and Edward Kai-Hua Chow 1,2,3*

Abstract

Compelling evidence have demonstrated that bulk tumors can arise from a unique subset of cells commonly termed “cancer stem cells” that has been proposed to be a strong driving force of tumorigenesis and a key mechanism of therapeutic resistance. Recent advances in epigenomics have illuminated key mechanisms by which epigenetic regulation contribute to cancer progression. In this review, we present a discussion of how deregulation of various epigenetic pathways can contribute to cancer initiation and tumorogenesis, particularly with respect to maintenance and survival of cancer stem cells. This information, together with several promising clinical and preclinical trials of epigenetic modulating drugs, offer new possibilities for targeting cancer stem cells as well as improving cancer therapy overall.

Keywords: Cancer stem cells, Epigenetics, Histone methylation, Histone methyltransferase, DNA methylation, Signaling pathway

Background

Advances in genomic and epigenomic research has shaped our understanding of cancer over the past two decades. Rather than merely a perpetuating mass of dysregulated cells growing in an uncontrolled manner, cancer is also defined by the dynamic genetic and epigenetic alterations that contribute to cancer initiation and progression. Since epigenetic changes such as DNA methylation and histone modifications are crucial factors in developmental programming of stem cells to specific lineages of cellular and tissue differentiation, aberrant epigenetic alterations may transform normal stem cells to cancer stem cells with the loss of differentiation capacity and the acquisition of stem-like characteristics. More importantly, epigenetic mechanisms have been shown to be implicated in the observed variability of treatment response. For instance, a small subset of cells has been shown to be resistant to drug therapy in a variety of cancers such as melanoma, gastric, colon and lung cancers as a result of aberrant expression of key epigenetic modifiers. In this review, we will focus our discussion on the epigenetic regulation of CSCs and their impact on tumor-initiation, progression and response to therapies.

Main text

Cancer stem cells (CSCs)

Cancer stem cells (CSCs) define a small, unique subset of cells with self-renewal ability and the capacity to generate the different cell types that constitute the whole tumor [1]. These cells are termed CSCs because of their “stem-like” properties commonly shared with normal tissue stem cells. Such properties include extensive self-renewal ability (symmetrical and asymmetrical) and differentiation capacity. It should be noted that a general capacity to differentiate is not a mandatory feature of CSCs and that the ability of CSCs to differentiate and repopulate the cell types found in the original tumor is of greater significance. More importantly, CSCs should demonstrate potent tumor-initiation capacity. This property is usually demonstrated by injecting limited number of CSCs into an orthotopic in vivo environment to generate the bulk tumor. Nevertheless, the concept of CSC is of significant importance as it highlights the need to eradicate the CSC populations to achieve an effective cure.

The first clear evidence of CSCs being a key tumor-initiating subset of cancer cells was demonstrated in acute myeloid leukemia (AML) where prospective CSCs were isolated using cell surface markers that identify normal haematopoietic stem cells and evaluated for their
tumor-initiating properties [2, 3]. Since then, similar identifications of tumor-initiating populations have been identified in multiple solid tumors that includes brain, breast, liver, ovary, prostate, lung, melanoma and colon cancers, by using different cell surface markers or through side population (SP) analysis [4–11]. For instance, in malignant glioma and medulloblastoma tumors, a putative neural stem cell marker, CD133 has been demonstrated to be adequate and essential to initiate and recapitulate the tumor upon xenotransplantation into immune-compromised mice [5]. However, this finding has been disputed as tumors can also arise from CD133-negative cells in a subset of glioma tumors [12]. In addition, CD133 surface marker expression has been demonstrated to change according to disease state and progression, further complicating its role as a bona fide CSC marker in brain tumors [13, 14]. In liver cancers such as hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), similar use of cell surface markers such as epithelial cell adhesion molecule (EpCAM), cytokeratin 19 (CK19), CD133, CD90, CD44, CD24, and CD13 has been applied to define a subpopulation of liver cancer cells as CSCs [15]. Importantly, it has recently been shown that these CSC markers are not specific to liver CSCs, and that distinct populations of liver CSCs express different surface markers possibly due to the strong intra- and inter-heterogeneity and varied etiology of liver cancer [16]. As a result, CSC studies have begun to move away from the reliance of cell surface markers to identify tumor-initiating cells and have begun to identify other complementary methods of measuring the functional activities of CSCs that may serve to identify CSCs as well as the molecular mechanisms that regulate CSCs [17].

Currently, the central theme of the CSC model is the ability of a subset of cells at the apex of the hierarchy to promote tumors and propagate tumor progression as compared to the non-tumorigenic cells within the bulk tumor. One of the gold standards to functionally identify CSCs is the capacity of these cells to regenerate a phenotypic copy of the original tumor in an orthotopic transplantation model. Non-CSCs, by definition, lack this ability and fail to generate tumors in the transplantation model(11,895),(992,996). It is important to note that the CSC hierarchy model may not be ubiquitous for all cancers and that some tumorigenic cells are common in certain cancers. It is also important to note that such transplantation assays measure the tumorigenic potential of the cells to form tumors and not their actual fate. For example, alterations in tumorigenic assays carried out by Quintana and colleagues showed that CSC frequency could be increased by changing several experimental parameters such as the use of extracellular matrix (ECM) in the form of matrigel, prolonging the duration for tumor formation, and varying the severity of immune-compromised mice used [18]. This study highlighted that the tumor-initiating capacity may be an artificial consequence of the conditions employed in xenograft mouse models.

While analyzing CSC surface marker expression in primary tumors has been often performed to study the clinical impact of CSCs on tumor progression, more often than not, this has resulted in ambiguous data possibly due to the fact that CSC properties that sustain the primary tumor phenotype are defined by more than just specific marker expression [19, 20]. Analysis of key signalling pathway activity that resembles those functioning in stem-like cells, is more likely to accurately interrogate the clinical contribution of CSCs. An example of such studies was carried out by Lim et al. in BRCA1 mutation-associated breast tumors, where the authors prospectively isolated distinct subpopulations of normal and tumorigenic epithelial cells from BRCA1 mutation heterozygous individuals and found that luminal progenitors were highly represented in BRCA1 mutation-associated breast tumors, more than the stem cell population [21]. This suggests that luminal progenitors are more likely the cells-of-origin for BRCA1 mutation-associated breast tumors, which was later confirmed in a transgenic mouse model study carried out by Molyneux and colleagues [22]. These studies highlight the predictive capability of gene expression mapping of pathway activation rather than specific marker identity. In a separate study, John Dick and colleagues demonstrated that tumor-initiating AML stem cells contribute to disease progression and patient survival outcome, underscoring the importance of functionally defining the CSCs [23]. More importantly, the contribution of CSCs, with preferential activation of core stem cell programs, to patient survival outcome has been demonstrated. The study by Shats et al. showed that a stemness gene signature derived from embryonic stem cells (ESCs) could predict a breast cancer patient cohort sensitive to drugs linked to this signature using a Connectivity Map [24], demonstrating the clinical contribution of CSCs to patient outcome [25]. Collectively, these studies highlight that CSCs that perpetuate tumors are not merely defined by surface marker expression, but more importantly and more accurately by their gene expression profiles and consequent pathway activations.

**Epigenetics: normal and cancer stem cells**

Epigenetic regulation of the genome is one of the primary means by which genetic code is altered to control cellular developmental hierarchies. Epigenetic mechanisms such as histone modifications, DNA methylation, chromatin remodelling and even changes in noncoding RNAs including miRNAs together govern the epigenome
landscape that dictate the outcome of cell fate specification without changes to the DNA sequences. Such changes in the genome is important during normal mammalian development and ESCs differentiation [26]. Importantly, gene expression profiles change during cellular differentiation according to not only a network of transcription factors but also the “epigenomic landscape” of the cell. For the purpose of this review, we will focus our discussions on two primary mechanisms of epigenetic regulation: histone modifications and DNA methylation.

Histone methylation occurs predominantly on lysine (K) and arginine (R) residues and these methylation marks serve as docking sites for histone readers [27]. Both lysine and arginine methylation can occur on both histones and non-histone proteins. The highly conserved histone lysine methylation occurs at three different levels: mono-, di-, and tri-methylation. Such modifications are commonly associated with gene activation or repression, depending on the target histone modification. For instance, histone H3 lysine 4 (H3K4), histone H3 lysine 36 (H3K36), and histone H3 lysine 79 (H3K79) are associated with gene activation whereas histone H3 lysine 9 (H3K9), histone H3 lysine 27 (H3K27) and histone H4 lysine 20 (H4K20) are associated with gene repression. The N-terminal tails of histones frequently undergo other post-translational modifications, which play significant roles in various DNA-templated processes, including transcription [28]. Hence, aberrations in histone modifications can lead to deregulated gene expression as seen in various human disease and malignancies.

DNA methyltransferases (DNMTs) are a class of enzymes involved in transferring a methyl group from S-adenosyl methionine (SAM) to cytosine bases of CpG dinucleotides at gene promoters and regulatory regions [29]. CpG dinucleotides are concentrated in short CpG-rich regions known commonly as “CpG islands”. In humans, CpG islands occupy about 60% of the gene promoters. CpG promoter islands can be methylated during development that results in long-term gene silencing. One classic example of such naturally occurring CpG methylation is the X-chromosome inactivation and the imprinted genes. DNA hypermethylation has also been associated with the silencing of tumor suppressor genes as well as differentiation genes in various cancers [30]. The reduced expression of these genes may then contribute to the formation of CSCs within tumor cell populations [31, 32]. Indeed, the importance of DNA methylation in maintaining CSC properties have been reported in leukemic, lung and colon stem cells [33–35]. The accumulation of epigenetic abnormalities has been suggested to be an early event that predisposes these tumor cells to acquire further mutations and genomic instability. This is supported by the fact that epigenetic machinery is crucial for the maintenance of normal stem and progenitor cells and that any epigenetic deregulation can lead to accumulation of cells with increased stemness properties and self-renewal ability, thus giving rise to CSCs.

### Key CSC pathways regulated by epigenetic mechanisms

#### Wnt/β-catenin signaling pathway

The canonical Wnt/β-catenin signaling pathway mediates gene activation through the transcription factor β-catenin. In the absence of Wnt signaling, cytoplasmic β-catenin is inactivated by a degradation complex comprising Adenomatous polyposis coli (APC), Axin, glycoprotein synthase kinase 3 beta (GSK-3β), and casein kinase 1 (CK1). Phosphorylation by GSK-3β targets β-catenin for ubiquitination and subsequent proteasomal degradation. Upon Wnt ligand binding to Frizzled receptors, the degradation complex is inactivated via low density lipoprotein receptor-related protein 5/6 (LDR5/6) and Dishevelled, allowing for stabilisation of β-catenin. Accumulated β-catenin then translocates into the nucleus, where it associates with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to induce transcription of Wnt target genes such as **CCND1** and **MYC**. The Wnt/β-catenin pathway has important functions in normal tissue development and maintenance, as well as in self-renewal and differentiation of CSCs [36, 37]. In fact, the Wnt/β-catenin pathway has been found to be aberrantly activated in a variety of cancers, either via genetic alterations, such as mutations in **CTNNBI**, **APC** and **AXIN** genes [38–40], or through epigenetic modulation.

DNA methylation has been linked to aberrant Wnt/β-catenin pathway activation through the enhanced promoter methylation and subsequent silencing of various Wnt inhibitors such as Wnt inhibitory factor 1 (**WIF-I**), **AXIN2**, Secreted frizzled-related protein 1 (**SFRP-1**), and Dickkopf-related protein 1 (**DKK1**) in breast and colorectal cancers [41–43]. In gastric cancer, Yoda et al. showed that aberrant methylation of Wnt negative regulators, including **DKK3**, Naked cuticle homolog 1 (**NKD1**) and **SFRP1**, could lead to activation of Wnt/β-catenin pathway [44]. Deregulation of Wnt/β-catenin pathway in cancer is also mediated by aberrant histone modifications. Decreased acetylation of H3K16 and increased H3K27 trimethylation along with recruitment of Sirtuin 1 (SirT1), enhancer of zeste homolog 2 (EZH2) and suppressor of zeste 12 protein homolog (Suz12) (components of polycomb repressor complex 2, **PCR2**) to the promoter of **DKK1** inhibited the expression of the **DKK1** Wnt antagonist (Fig. 1) [45]. In colorectal cancer, Dishevelled-binding antagonist of beta-catenin 3 (**DACT3**), an antagonist of Dishevelled, was found to be regulated by
bivalent histone modifications—activating H3K4me3 and repressive H3K27me3 histone marks—at its locus [46]. This bivalent histone state was associated with decreased DACT3 expression in colorectal cancer cell lines [46]. In addition, methylation of H3K4 at the regulatory element of DKK1 marks the site for binding by the transcription factor Achaete-scute family BHLH transcription factor 1 (ASCL1), resulting in a repressed chromatin configuration [47]. ASCL1-mediated inhibition of DKK1 consequently leads to activation of Wnt signaling, and ASCL1 was found to be crucial for glioblastoma CSC maintenance and tumorigenicity [47–49].

Besides alterations in DNA and histones, non-coding RNAs have also been found to act as epigenetic modulators of Wnt/β-catenin signaling. Wang et al. demonstrated that long non-coding RNA of transcription factor 7 (lncTCF7), which is highly upregulated in liver CSCs, is able to induce TCF7 expression by recruiting the Switch/sucrose non-fermentable (SWI/SNF) chromatin remodelling complex to its promoter [50]. This subsequently activates the Wnt pathway, leading to self-renewal of liver CSCs and tumor propagation.

**Hedgehog signaling pathway**

The Hedgehog (Hh) signaling pathway plays important roles in guiding cell fate during embryonic development and in maintaining adult tissue homeostasis [51, 52]. It also functions in regulating stem and progenitor cell proliferation and maintenance in several tissues [53]. In the absence of sonic hedgehog ligand (Shh), the Patched receptor (PTCH1) prevents activation of Smoothened (SMO), allowing Gli proteins to be sequestered by suppressor of fused homolog (SUFU) and kinesin family member 7 (Kif7). Upon Shh binding to PTCH1, SMO is activated and mediates Hh signaling transduction via release of Gli proteins, which then enter the nucleus and act as transcription factors. Gli1 activates transcription of Hh target genes, Gli2 can both activate and repress transcription, while Gli3 functions as a transcriptional repressor.
The Hh signaling has been implicated in tumorigenesis in various tissues [54]. In basal cell carcinoma (BCC), upregulation of Hh signaling in stem cells in the interfollicular epidermis [55] or within the hair follicle [56] has been reported to contribute to tumor formation. In medulloblastomas, granule neuron progenitors/precursors (GNPs) in the cerebellum that have constitutively active Hh signaling have been identified as cells-of-origin of the tumor [54, 57, 58].

The Hh pathway is activated by genetic mutations in both BCC and medulloblastoma. However, epigenetic mechanisms also play a role in modulating the expression and function of Hh pathway components in various tumors. The chromatin remodelling protein SNF5 directly interacts with Hh signaling effector Gli1 to down-regulate expression of Hh target genes. SNF5 is a member of the SWI-SNF complex and inhibits gene expression by altering chromatin structure at Gli1-regulated promoters, which includes genes such as Ptc1 and Gli1 itself. Hence, inactivation of SNF5 would contribute to aberrant Hh signaling activity as seen in human malignant rhabdoid tumors [59–61].

In addition, histone deacetylases are also involved in regulating Gli protein function. Gli1 and Gli2 proteins require deacetylation by HDAC1 to be transcriptionally active, and they, in turn, can induce HDAC1 expression through a positive autoregulatory loop [62]. This mechanism is inhibited by E3-ubiquitin ligase complex (comprising Cullin3 and renin, REN)-mediated degradation of HDAC1. However, REN is often deleted in human medulloblastoma [63], resulting in increased levels of HDAC1 and Gli1, and subsequent deregulation of Hh signaling in neural progenitors and tumor cells [62].

Hh pathway can also be epigenetically regulated by aberrant DNA methylation. Studies have found that hypomethylation of Shh promoter leads to enhanced expression of Shh ligand in breast and gastric cancers (Fig. 1) [64, 65]. Indeed, Duan and colleagues reported that promoter hypomethylation allowed nuclear factor kappa b (NF-κB) to bind and activate transcription of Shh, resulting in overexpression of the ligand [66]. Consequently, the upregulation of Hh signaling was able to promote self-renewal and invasiveness in breast cancer cells [66].

**Notch signaling pathway**

Notch is a transmembrane receptor involved in cell contact-dependent signaling [67]. Binding of ligands Jagged1/2 or Delta1-4 triggers cleavage of Notch intracellular domain (NICD) by y-secretase and its release into the cytoplasm [68]. NICD then translocates into the nucleus, where it interacts with recombination signal binding protein for immunoglobulin kappa J region (RBPJ-κ) to transcriptionally induce expression of Notch target genes, such as MYC and HES1 [69]. In the inactive state, RBPJ-κ recruits co-repressor complexes to suppress Notch target genes [70].

Notch signaling is an evolutionarily conserved pathway that has important roles in development of various tissues and organs [71]. It also regulates cell proliferation and differentiation across a wide range of cell types and during different stages of cell lineage progression [69]. Furthermore, Notch pathway modulates stem cell differentiation and self-renewal. Importantly, Notch signaling has been shown to be crucial for survival of neural stem cells (NSCs) [72]. In murine intestinal stem cells, loss of B-lymphoma Mo-MLV insertion region 1 homolog (Bmi1), a target of Notch signaling, decreases proliferation and induces cellular differentiation into goblet cells [73]. Deregulation of Notch pathway has been implicated in various tumors such as prostate cancer, breast cancer, lung cancer, colorectal cancer and hematological malignancies [74–77]. Recent studies have also reported the role of Notch signaling in breast, colon and oesophageal CSCs [78–80].

Epigenetic modifications affecting various components of the Notch pathway have been found to cause aberrations in Notch signaling activity. Overexpression of Notch ligand Jagged2 in multiple myeloma has been associated with enhanced histone acetylation at the JAGGED2 promoter region [81]. Nuclear co-repressors such as nuclear receptor co-repressor 2 (SMRT) normally recruit HDACs to promoter regions to regulate gene expression. However, in multiple myeloma, the decreased levels of nuclear co-repressor SMRT reduces HDAC recruitment to JAGGED2 promoter, resulting in increased transcription of the Notch ligand and subsequent activation of Notch signaling [81]. In addition, Jin et al. reported that serine-threonine kinase receptor-associated protein (STRAP) promotes stemness in colorectal cancer-initiating cells via modulating the Notch pathway [80]. They found that STRAP interacts with EZH2 and SUZ12 of PRC2 complex, inhibiting histone methylation of H3K27 on HES1 and HESS promoters, leading to gene activation (Fig. 1). This was concordant with the finding that both genes had increased activating (H3K4me3) and decreased repressive (H3K27me3) histone marks in wild-type (WT) cells as compared to STRAP knockdown (KD) cells. Moreover, ectopically expressed HES1 or HESS was able to rescue the stemness phenotype in STRAP KD cells [80], further demonstrating the significance of Notch signaling in regulating stemness potential in CSCs.

**Epigenetic regulation of metastasis and chemoresistance pathways**

During tumor progression, metastasis of tumor cells has been linked to the induction of epithelial-to-mesenchymal
transition (EMT). EMT is a multi-step process that results in decreased cell-cell adhesion, loss of cell polarity, increased cell motility, and gain of invasive mesenchymal properties [82, 83]. There is evidence that activation of EMT can confer cells with CSC and tumor-initiating properties [84, 85]. It was reported that EMT induction in both immortalised and transformed human mammary epithelial cells resulted in increased expression of CSC markers and mammosphere formation. Moreover, stem-like cells of mammary carcinomas were also found to express markers of EMT [85]. The relationship between EMT and acquisition of stem-like properties in tumor cells suggests that stemness properties may help increase the chances of disseminated tumor cells to successfully metastasize to distant sites [70].

Several signaling pathways involved in embryonic development, such as Wnt, Hedgehog and Notch, have been identified to regulate the EMT process [86, 87]. The transforming growth factor-β (TGF-β) family of cytokines are also known inducers of EMT [88, 89]. Hence, deregulation of these pathways and proteins could activate aberrant EMT induction, resulting in tumor metastasis and contribute to poorer patient prognosis. A hallmark of EMT is the loss of membrane protein E-cadherin, which functions in maintaining cell-cell adhesion [90–92]. Loss of E-cadherin can arise from mutations in its encoding gene CDH1, or via mechanisms that regulate its expression and function, including transcriptional repressors Twist-related protein 1 (TWIST1), Snail family zinc finger 1 (SNAI1), Zinc finger E-box-binding homeobox 1 (ZEB1) and Zinc finger E-box-binding homeobox 2 (ZEB2) [93]. Epigenetic mechanisms have also been found to play a dynamic role in silencing E-cadherin expression. For instance, DNA methylation of E-cadherin promoter helps to recruit HDACs to the site, leading to histone deacetylation and transcriptional silencing [94, 95]. In addition, histone methylation of CDH1 promoter by EZH2 and PRC2 complex, which is recruited by SNAI1, also represses E-cadherin expression [96, 97].

Micro RNAs (miRNAs) that regulate the EMT pathway are epigenetically regulated as well. MiR-200 family members and miR-205 repress EMT and invasion by directly inhibiting transcription factors ZEB1 and ZEB2 [98–100]. Hence, inhibition of these miRNAs would result in increased EMT and metastasis. This is observed in high-grade breast cancers, whereby low levels of miR-200c is correlated with upregulation of EMT and stemness markers [101]. Silencing of miR-200c and miR-205 expression can also occur via enrichment of H3K27me3-mediated chromatin remodelling and DNA methylation, which leads to induction of EMT and CSC phenotype in immortalised human bronchial epithelial cells [102].

Studies have shown that cells with both CSC properties and EMT-like phenotype tend to be more resistant to chemotherapy drugs as compared to other cancer cell populations [103–105]. Arumugam et al. demonstrated that pancreatic cancer cell lines with EMT features were resistant to common chemotherapy drugs such as gemcitabine, 5-fluorouracil and cisplatin [106]. Moreover, cells that were resistant to gemcitabine expressed high ZEB1 and low E-cadherin, and acquired greater cell migration ability [106]. Indeed, these findings indicate that epigenetic modulations involved in the gain of CSC and EMT properties would most likely impact tumor cells' response to therapy.

The increased drug resistance observed in CSCs is commonly mediated by enhanced expression of drug efflux transporters, such as ATP-binding cassette (ABC) family of transporters, which includes ATP-binding cassette sub-family G member 2 (ABCG2), multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 1 (MRP1) [17, 107, 108]. These drug transporters utilise ATP in moving drugs out of the cell against its concentration gradient. The expression of these transporters are regulated by various mechanisms and pathways, and their deregulation would result in an enrichment of these proteins and drug efflux capability. Studies have shown that MRP1 expression can be upregulated by Notch signaling, and is responsible for drug resistance in CSCs [109, 110]. Expression of ABCG2 is upregulated upon enrichment of permissive histone modifications such as greater histone H3 acetylation, increased H3K4 tri-methylation and phosphorylation of H3S10, as well as decreased HDAC1 levels [111]. These histone marks along with decreased H3K9 tri-methylation allow RNA polymerase II and chromatin remodelling protein Brahma-related gene 1 (Brg1) to gain access to the promoter and activate transcription of ABCG2 [111]. Collectively, a complex network of signaling pathways that function in modulating the activity of normal stem cells can be susceptible to deregulation as a result of aberrant epigenetic modifications during the course of tumor formation. These abnormal alterations in key signaling pathways contribute to CSC proliferation and maintenance, as well as tumor progression and invasion. Hence, epigenetic regulation of these signalling pathways may serve as potential mechanisms for targeted therapy against CSCs.

**Therapeutic intervention using epigenetic modifying drugs**

As epigenetic mechanisms have important functions in modulating stem cell properties in cancer cells, targeting components of these epigenetic pathways would help in eradicating both CSCs and the bulk tumor population. Inhibitors of epigenetic modulatory enzymes such as HDACs and DNMTs have been widely studied and many are currently in clinical trials for treatment of a variety of cancers. In addition, deregulation of chromatin
remodelling has been associated with tumorigenesis and tumor progression, thus making chromatin remodelling proteins viable targets for small molecule inhibitors as well. Indeed, many of these therapeutic strategies aim to induce differentiation of CSCs and to sensitize these cells to chemotherapy, with the ultimate goal of reducing tumor relapse and improving patient survival. Here, we review the development of various epigenetic therapies designed to target different components of the epigenetic machinery. A summary of these epigenetic drugs and their clinical status can be found in Table 1.

**Targeting DNA methylation - DNA methyltransferase (DNMT) inhibitors**

Inhibitors of DNA methylation were among the first epigenetic drugs tested for use in treatment of cancer [112]. The most widely studied DNMT inhibitors include azacitidine (5-azacitidine) and decitabine (5-aza-2′-deoxycytididine), which act as analogues of cytosine. These molecules get incorporated into DNA and covalently bond with DNA methyltransferase, thus preventing its function [113, 114] and leading to its degradation [115]. These drugs were initially used as cytotoxic chemotherapeutics in the late 1960s [116], but were found to be highly toxic [117–120]. Subsequently, recent studies have discovered that low doses of DNMT inhibitors had greater efficacy in sustaining decreased DNA methylation and associated re-expression of silenced genes in leukemic and epithelial tumor cells [121]. These lower doses were also able to reduce tumorigenicity and target CSC populations within the tumor. In lung cancer, Liu et al. showed that inhibition of DNMT1 was able to decrease proliferation and tumorigenic ability of lung CSCs [34].

Multiple studies have also demonstrated the role of DNMT inhibitors in differentiation therapy. Pinto et al. showed that azacitidine could induce primary AML cells from patients to differentiate into less or non-malignant cells [122, 123]. Prostate cancer derived-CSCs that were treated with decitabine showed decreased expression of stemness genes Octamer-binding transcription factor 4 (OCT4O029 and Nanog homeobox (NANOG), leading to overall reduction in tumor growth [124]. In addition, low doses of SGI-110, a newer DNMT inhibitor, was recently reported to be capable of reprogramming ovarian CSCs to a more differentiated state [125]. Treatment with SGI-110 also decreased tumor-initiating ability and re-sensitized these cells to platinum, suggesting a potential use of DNMT inhibitors in combination with other chemotherapeutic agents in preventing recurrence of ovarian cancer [125]. Both azacitidine and decitabine have been approved by the FDA for treatment of myelodysplastic syndrome (MDS) [126]. Clinical trials for other indications such as AML and colorectal cancer are still ongoing. SGI-110 is also in phases of clinical trials for treatment of various cancers such as AML, MDS, liver cancer and platinum-resistant ovarian cancer.

**Targeting histone deacetylation - Histone deacetylase (HDAC) inhibitors**

An important histone tail modification is acetylation, which is regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs are responsible for adding an acetyl group onto lysine residues of histone tail, which neutralizes the positive charge, resulting in a more “open” chromatin structure [127]. In contrast, HDACs remove the additional acetyl group, leading to increased binding affinity between DNA and histones, which is generally associated with gene repression [128]. Very often, deregulated gene silencing in cancers has been associated with aberrant histone deacetylation. For instance, in leukemia, this can be mediated through aberrant recruitment of HDACs by fusion proteins such as Acute myeloid leukemia protein 1 Eight twenty-one protein (AML1-ETO) and Promyelocytic leukemia protein retinoic acid receptor alpha (PML-RARα), which leads to abnormal gene silencing and subsequent leukemogenesis [129, 130]. Besides, HDACs can also acetylate non-histone proteins, including tumor suppressor p53 and oncogene B-cell lymphoma 2 (BCL2), resulting in inhibition of p53-dependent transcription [131] and upregulation of pro-survival protein, BCL2 [132]. Hence, the use of HDAC inhibitors in returning histone acetylation patterns to a normal state has been found to be effective in inducing apoptosis and differentiation as well as inhibit proliferation of tumor cells [129, 133]. These HDAC inhibitors can be divided mainly into two classes—the pan HDAC inhibitors and the class-specific inhibitors [134], and they all function via chelating the zinc atom in the active site of the enzyme [127].

Two HDAC inhibitors, vorinostat (suberoylanilide hydroxamic acid) and romidepsin (depsipeptide), have been approved for treatment of cutaneous T-cell lymphoma [135, 136]. Both drugs were found to produce durable response and efficacy in patients with cutaneous T-cell lymphoma in Phase 2 multi-center trials [135–138]. However, besides cutaneous T-cell lymphoma, monotherapy of vorinostat and romidepsin in treatment of various solid tumors have had little success in clinical trials [139–150]. Apart from these two compounds, many other HDAC inhibitors have also been developed and tested in clinical trials, the details of which have been well-reviewed elsewhere [115, 151–153]. Monotherapies of these compounds, including panobinostat [154, 155], entinostat [156, 157], belinostat [158, 159] and pracinostat (SB939) [160], are being tested against various hematological malignancies and solid tumors.
| Drug          | Target                                      | Clinical status                      | Indication                                                  | References          |
|--------------|---------------------------------------------|--------------------------------------|-------------------------------------------------------------|---------------------|
| **DNMT inhibitors** |                                           |                                      |                                                             |                     |
| Azacitidine  | Inhibit DNMT (act as nucleoside analog)    | FDA-approved                         | MDS                                                        | [277, 278]          |
| Decitabine   | Inhibit DNMT (act as nucleoside analog)    | FDA-approved                         | MDS                                                        | [115, 277]          |
| SGI-110      | Inhibit DNMT by incorporating into guanine nucleotide | Phase 3 (NCT02348489)                   | AML, MDS, AML, Advanced HCC, Platinum-resistant recurrent ovarian cancer | [279–281]          |
|              |                                             | Phase 1/2 (NCT01752933)               |                                                             |                     |
|              |                                             | Phase 2 (NCT02197676)                 |                                                             |                     |
|              |                                             | Phase 2 (NCT01261312)                 |                                                             |                     |
|              |                                             | Phase 1/2 (NCT01696032)               |                                                             |                     |

| **HDAC inhibitors** |                                           |                                      |                                                             |                     |
| Vorinostat     | Inhibitor of Class I and II HDACs          | FDA-approved                         | Cutaneous T cell lymphoma                                  | [135]              |
| Romidepsin     | Inhibitor of Class I HDACs                | FDA-approved                         | Cutaneous T cell lymphoma                                  | [136]              |
| Panobinostat   | Pan-HDAC inhibitor                         | Phase 3 (NCT01034163)                | Hodgkin’s lymphoma                                          | [282, 283]         |
|                |                                             | Phase 2/3 (NCT00425555)              | Cutaneous T cell lymphoma                                  |                     |
| Entinostat     | Inhibitor of Class I HDACs                | Phase 2 (NCT00866333)                | Hodgkin’s lymphoma                                          | [284]              |
|                |                                             | Phase 1/2 (NCT01038778)              | Clear cell renal cell carcinoma, metastatic renal cell cancer |                     |
| Belinostat     | Inhibitor of Class I and II HDACs          | Phase 2 (NCT00357032)                | Relapsed/refractory AML or older patients with newly diagnosed AML | [285–287]         |
|                |                                             | Phase 2 (NCT00274651)                | Recurrent/refractory cutaneous and peripheral T cell lymphomas |                     |
|                |                                             | Phase 2 (NCT00301756)                | Ovarian cancer                                              |                     |
| Pracinostat    | Inhibitor of Class I and II HDACs          | Phase 2 (NCT0112384, NCT01075308)    | Translocation-associated recurrent/metastatic sarcomas, metastatic prostate cancer | [288, 289]        |
| Givinostat     | Inhibitor of Class I and II HDACs          | Phase 2 (NCT01761968)                | Chronic myeloproliferative neoplasms                        | [290]              |
| Valproic acid  | Inhibitor of Class I and II HDACs          | Phase 2 (NCT01900730)                | Breast cancer                                               | [163, 291]         |
| **HMT inhibitors** |                                           |                                      |                                                             |                     |
| EPZ-5676       | Inhibit DOT1L methyltransferase (H3K79) activity by competing with SAM | Phase 1 (NCT02141828, NCT01684150) | MLL-fusion leukemia, AML, acute lymphocytic/lymphoblastic leukemia, MDS, myeloproliferative disorders | [182]              |
| DZNep          | Inhibit HMT activity of EZH2 via inhibiting S-adenosylhomocysteine (SAH) hydrolase | Not in trial | Breast cancer, prostate cancer, glioblastoma multiforme (GBM) | [193, 292, 293]    |
| E7438 (EPZ-6438) | Inhibit HMT activity of EZH2 by competing with co-factor S-adenosyl-methionine (SAM) | Phase 2 (NCT02860286, NCT02601950) | Malignant mesothelioma, rhabdoid tumors, synovial sarcoma, epithelioid sarcoma | [196]              |
| GSK2816126 (GSK126) | Inhibit HMT activity of EZH2 by competing with co-factor S-adenosyl-methionine (SAM) | Phase 1 (NCT02082977) | Relapsed/refractory DLBCL, transformed follicular lymphoma, multiple myeloma, non-Hodgkin’s lymphoma, solid tumors | [198, 199]         |
| CPI-120S       | Inhibit HMT activity of EZH2 by competing with co-factor S-adenosyl-methionine (SAM) | Phase 1 (NCT02395601) | B-cell lymphoma                                            | [294]              |
Another mechanism of action of HDAC inhibitors for cancer treatment is via differentiation or reprogramming of cancer cells. As therapy resistance is a major hurdle in cancer treatment and is often associated with CSCs and epigenetic control [161], HDAC inhibitors possess the ability to induce differentiation of CSCs from their quiescent state, thereby re-sensitising them to other chemotherapy agents. Valproic acid, an antiepileptic drug, has been found to be a powerful HDAC inhibitor [162]. Gottlicher et al. demonstrated that valproic acid could trigger differentiation of transformed hematopoietic progenitor cells and leukemic blasts from AML patients [162]. Furthermore, Travaglini et al. found that valproic acid was able to epigenetically reprogram breast cancer cells into a more “physiologic” phenotype, thus improving sensitivity to other forms of breast cancer therapy [163]. In addition, entinostat, a selective inhibitor of class I HDACs, was recently reported to reverse EMT phenotype and decrease the population of tumor-initiating cells in triple-negative breast cancer (TNBC) [164]. These tumor-initiating cells possessed CSC properties and were responsible for driving metastasis and drug resistance in TNBC, thus contributing to poor patient prognosis. Hence, this study demonstrated the utility of HDAC inhibitors in preventing CSC invasiveness and tumor metastasis. Overall, these studies demonstrate the potential use of epigenetic modulators towards the differentiation and therapeutic sensitization of CSCs.

### Table 1 Epigenetic modulators in cancer (Continued)

| Modulator | Effect | Phase/Status | Cancer Types |
|-----------|--------|--------------|--------------|
| Chaetocin | Inhibit SUV39H1 | Not in trial | HCC, multiple myeloma [216, 218] |
| BIX01294 | Inhibit G9a (substrate-competitive) | Not in trial | Breast cancer, colon cancer [209, 212] |
| UNC0638 | Inhibit G9a (substrate-competitive) | Preclinical | Breast cancer [213] |
| UNC0642 | Inhibit G9a (substrate-competitive) | Preclinical | Pancreatic cancer [214] |
| HDM inhibitors | Tranylcypromine | Irreversible inhibitor of LSD1 | Phase 1 (NCT02273102, NCT02717884), Phase 1/2 (NCT02261779) | AML, MDS, AML [226] |
| | ORY-1001 | Irreversible inhibitor of LSD1 | Phase 1 | AML [227] |
| | GSK2879552 | Irreversible inhibition of LSD1 (activity by modifying its cofactor FAD) | Phase 1 (NCT02034123, NCT02177812) | Small cell lung cancer, AML [231] |
| | GSK-J4 | Inhibit UTX | Not in trial | T-cell acute lymphoblastic leukemia (T-ALL) [295] |
| BET inhibitors | I-BET762 (GSK525762A) | Interfere with binding of BET proteins to acetylated histones | Phase 1 (NCT01587703, NCT01943851) | Solid tumors, relapsed refractory haematological malignancies [243, 244] |
| | JQ1 | Interfere with binding of BET proteins to acetylated histones (greatest specificity for BRD3 and BRD4) | Not in trial | NUT midline carcinoma (NMC), multiple myeloma, AML, Burkitt’s lymphoma, DLBCL [239, 240, 296, 297] |
| | I-BET151 (GSK1210151A) | Interfere with binding of BET proteins to acetylated histones | Not in trial | MLL fusion leukemia, medulloblastoma [298, 299] |
| | OTX015 | Interfere with binding of BET proteins to acetylated histones | Phase 1 (NCT01713582) | Hematological malignancies [248, 297] |
| | CPI-203 | Interfere with binding of BET proteins to acetylated histones | Not in trial | Lymphoma [300] |
| | CPI-0610 | Interfere with binding of BET proteins to acetylated histones | Phase 1 (NCT02157636, NCT01949883, NCT02158858) | Acute leukaemia, MDS, myelodysplastic/myeloproliferative neoplasms, lymphoma, multiple myeloma [301] |

Targeting histone methylation – Histone methyltransferase (HMT) inhibitors

A class of enzymes called histone lysine methyltransferases (HKMTs) mediate the addition of a methyl group to
the nitrogen atom of the lysine side chain [165]. Despite catalysing a common chemical reaction, this family of HKMTs demonstrate large structural diversity of its active sites, allowing these enzymes to have high substrate specificity [127]. For example, DOT1L (KMT4) is a unique HKMT as it is currently the only known enzyme that methylates lysine 79 of histone H3 (H3K79) [166]. Similarly, methylation of H3K27 is only mediated by the catalytic subunit EZH2 (KMT6) of PRC2 [127]. In contrast, some methylation marks can be catalysed by several proteins, such as H3K9 methylation. These post-translational methylation of histones have important roles in regulation of gene expression, differentiation, DNA damage repair as well as in tumorigenesis [167, 168]. Aberrant histone methylation can be due to gene mutations, over-expression or deregulated control of epigenetic modulatory enzymes involved. Thus, HKMTs are potential therapeutic targets, and the structural differences between members of the family also enable greater selectivity in inhibition of these proteins by small molecule compounds [169].

HKMT inhibitors have only recently gained more attention as cancer therapeutics, resulting in a rapidly increasing number of these small molecule inhibitors being developed [170–172]. In fact, several DOT1 like histone H3K79 methyltransferase (DOT1L) and EZH2 inhibitors have progressed to being tested in clinical trials as cancer interventions [173]. H3K79 methylation by DOT1L is associated with transcriptional activation of genes under its regulation [174, 175], and overexpression or aberrant DOT1L activity has been found in cancer, such as leukemia with mixed lineage leukemia (MLL) gene translocation. The MLL fusion protein can recruit DOT1L into a transcription complex, which subsequently methylates H3K79 [176–180]. This leads to dysregulation and overexpression of many MLL-target genes, including Homeobox A9 (HoxA9) and Meis homeobox 1 (Meis1), which are key regulators of hematopoietic stem cell differentiation that contributes to leukemogenesis [165]. Therefore, DOT1L is an attractive target for therapy, resulting in the first selective DOT1L inhibitor EPZ-4777 to be synthesised with anti-tumor effects against murine models of MLL-rearranged leukemia [181]. Further optimisation of the drug led to the development of EPZ-5676, the first HKMT inhibitor to enter clinical trials. This compound has been shown to be highly potent and selective for DOT1L. Treatment with EPZ-5676 in a MLL-rearranged leukemia xenograft model showed durable and complete tumor regression [182]. EPZ-5676 is currently under clinical studies (Phase I) for MLL-fusion leukemia, AML, MDS and myeloproliferative disorders.

EZH2 is a member of PRC2, along with proteins embryonic ectoderm development protein (EED) and SUZ12, and is responsible for catalysing H3K27 mono-, di- and tri-methylation [183–185]. Overexpression of EZH2 has been found in various cancers of the breast, lung, prostate and haematological malignancies [186–191], and is associated with poor disease prognosis. Studies have also shown the role of EZH2 deregulation in tumor progression, metastasis [192, 193] and maintenance of CSC self-renewal properties [194]. In glioblastoma multiforme (GBM), inhibition of EZH2 by S-adenosylhomocysteine hydrolase (SAH) inhibitor 3-deazaneplanocin A (DZNep) was able to reduce self-renewal and tumor-initiating capabilities of GBM CSCs in vivo via affecting transcriptional regulation of oncogene MYC [193]. However, DZNep affects methylation of other histone residues [195], leading to the development of more specific EZH2 inhibitors. The earliest SAM-competitive and selective EZH2 inhibitor to advance into clinical trials for treatment of rhabdoid tumors and lymphomas is EPZ-6438 (E7438) [196, 197]. A more recent drug, GSK2816126 (GSK126) has also entered clinical studies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), multiple myeloma and transformed follicular lymphoma [198, 199]. Both drugs have shown high potency and selectivity in inhibiting tumor growth in preclinical studies [197, 198, 200].

H3K9 methyltransferases, such as euchromatic histone lysine methyltransferase 2 (G9a/EHMT2) and euchromatic histone lysine methyltransferase 1 (GLP/EHMT1), catalyse mono- and di-methylation of the lysine residue, while tri-methylation of H3K9 is mediated by Suppressor of variegation 3–9 homolog 1 (SUV39H1) and Suppressor of variegation 3–9 homolog 2 (SUV39H2) [201]. Upregulation of G9a activity has been linked to several types of cancer, including ovarian, lung, liver and bladder cancers [202–208]. Hence, several substrate-competitive inhibitors of these HKMTs have been developed. BIX-01294 is the first specific inhibitor of G9a and GLP, and studies have reported its ability to decrease H3K9me2 levels in mammalian cells [209–211]. Kim et al. reported that BIX-01294 was able to induce cell death in colon and breast cancer cells via EHMT dysfunction [212]. However, due to the increased toxicity levels of BIX-01294 at higher concentrations, the use of this drug is limited. This led to the recent development of a more potent, specific and selective EHMT inhibitor, UNC0638 that was found to decrease local H3K9me2 and DNA methylation levels [213]. Further development generated UNC0642, which possessed better pharmacokinetic properties and higher efficacy in inhibiting colony formation ability of pancreatic adenocarcinoma cells [214].

Methylation of H3K9 by SUV39H1 is associated with silencing of tumor suppressor genes, including E-cadherin and p15INK4B, in AML [215]. Overexpression of SUV39H1 has also been correlated with poor prognosis in multiple myeloma patients [216]. Treatment of
multiple myeloma cells with chaetocin, a small molecule inhibitor of SUV39H1 showed anti-tumor effects at low doses of the drug [216]. Similarly, chaetocin was found to decrease H3K9me3 levels and induce differentiation of AML cells at non-toxic doses [217]. Furthermore, chaetocin was able to repress cell proliferation and induce apoptosis in hepatocellular carcinoma (HCC) cultures and xenografts [218], implying a potential tumorigenic role of EHMTs in HCC progression and development.

**Targeting histone demethylation – Histone demethylase (HDM) inhibitors**

Methylation of lysine on histones is also regulated by histone lysine demethylases (KDMs). This group of epigenetic erasers function in removing the methyl groups from lysine side chains on histones [219, 220]. As proper functioning of both HKMTs and KDMs is required to maintain stable histone methylation levels, small molecule inhibitors have also been developed to target KDMs. KDMs can be grouped into two families - the lysine-specific demethylase (LSD) family and Jumonji domain-containing (JmjC) family [221]. The LSD family are flavin adenine dinucleotide (FAD)-dependent amine oxidases that demethylates mono- and di-methyl lysine residues, while JmjC enzymes utilise 2-oxoglutarate and iron to oxidatively release methyl groups from all three methylation states at lysine residues [172, 222].

Uregulated expression of LSD1 (KDM1A) has been found in various human cancers, including AML, ovarian, lung, bladder and colorectal cancers [223–225]. Hence, small molecule inhibitors of LSD1 that target the enzyme cofactor FAD have been developed, the first of which is tranylcypromine [226]. Further studies have led to the synthesis of more selective derivatives of tranylcypromine, such as ORY-1001 [227] and GSK2879552 [228]. They function by irreversibly changing FAD, leading to the formation of a tetracyclic adduct [229]. LSD1 is important for normal hematopoiesis; loss of LSD1 has been found to inhibit differentiation and impair hematopoiesis [230]. This suggests a potential role of aberrant LSD1 activity in affecting stemness properties in tumor cells. The inhibitor ORY-1001 has been shown to decrease the population of AML stem cells and improve survival of mice with acute lymphoblastic leukemia (ALL) in preclinical studies [227, 228]. GSK2879552 has also been found to influence differentiation in small cell lung cancer (SCLC) [231]. These compounds are currently in phase 1 studies for relapsed or refractory AML (ORY-1001) and SCLC (GSK2879552).

Similarly, JmjC demethylases are amenable to pharmacological intervention as well. Ubiquitously transcribed tetratricopeptide repeat X chromosome (UTX), also known as KDM6A, is responsible for demethylating H3K27 [232–234], and loss of UTX activity has been found in multiple human malignancies, including multiple myeloma, esophageal squamous cell carcinoma and renal carcinoma [166]. However, no inhibitors of JmjC enzymes have advanced beyond biochemical studies [127]. Nevertheless, as UTX is a component of the mixed lineage leukemia protein 2 (MLL2) H3K4 methyltransferase complex, and interacts with SWI/SNF chromatin remodelling complex [235–237], it is still an important epigenetic target and its role in epigenetic modulation still warrants further study.

**Targeting epigenetic readers – BET inhibitors**

While epigenetic modulatory enzymes are obvious targets for therapy, epigenetic readers are also important components of the epigenetic machinery as they directly or indirectly regulate gene expression. One such group of readers called bromodomain and extra-terminal (BET) proteins modulate gene expression by recognising acetylated histones. Increased BET activities have been associated with NUT midline carcinoma (NMC), glioblastoma and various haematological malignancies, through aberrant transcription of disease-associated genes and oncogenes such as \( \text{MYC} \) [238]. Hence, BET proteins appear to be attractive therapeutic targets for controlling dysregulated gene expression.

JQ1 is a selective BET inhibitor of BRD family of proteins, including Bromodomain-containing protein 4 (BRD4) [239]. In preclinical studies, JQ1 was able to cause tumor regression in NMC mouse models, inhibit proliferation, induce apoptosis and differentiation in cancer cells [239–242]. Another BET inhibitor, I-BET762 (GSK525762A), functions by binding to the acetyl-binding pocket of BET proteins [243, 244]. Studies have shown that I-BET762 treatment was able to induce terminal differentiation of patient-derived malignant cells [245] and activate apoptosis in neuroblastoma and prostate cancer via inhibition of Myc-driven pathways [246, 247]. This compound is currently in phase I trials for solid tumors and relapsed or refractory haematological cancers.

OTX015 is another BET inhibitor that has progressed into clinical trials for various haematological malignancies. This compound has been found to possess anti-proliferative effects via directly influencing \( \text{MYC} \) expression and activity [248, 249]. Similarly, CPI-0610 has also entered clinical testing for lymphoma, multiple myeloma and myelodysplastic or myeloproliferative neoplasms. I-BET151 is a pan-BET inhibitor, similar to JQ1, and has been found to block proliferation and induce apoptosis in myeloma cells via repressing Myc activity [250]. Antitumor effects have also been observed in NMC, MLL, ALL, lung cancer and brain cancer [238].
Combination therapy with epigenetic modulators

While epigenetic drugs have been tested preclinically and clinically as single agents, further studies have revealed the increased efficacy of these drugs when used in combination with other therapies. One common combination of different epigenetic therapies is that of DNMT and HDAC inhibitors. Pathania et al. reported that combining azacitidine (DNMT inhibitor) and butyrate (HDAC inhibitor) was capable of significantly decreasing breast cancer CSC population [251]. In addition, combination of azacitidine and HDAC inhibitor entinostat at low doses in a phase I/II clinical trial showed sustained and favourable responses in treatment-resistant non-small cell lung cancer (NSCLC) patients [252]. Azacitidine and valproic acid co-treatment was also able to promote tumor regression in Patched mutant mouse models of medulloblastoma [253]. Besides DNMT-HDAC inhibitor combination therapy, studies have demonstrated synergistic effects of other epigenetic drug combinations. For example, inhibiting both EZH2 and G9a histone methyltransferases showed greater efficacy in blocking cell proliferation as compared to single drug treatment [254]. Furthermore, the DOT1L inhibitor EPZ-5676 could interact synergistically with DNA hypomethylating agents, such as azacitidine and decitabine, in MLL-rearranged leukemia cells [255].

In recent years, an increasing number of studies have reported the use of epigenetic drugs in combination with conventional chemotherapeutics, with underlying mechanisms of re-sensitising resistant CSCs to drug treatment, or to prime cancer cells for subsequent therapies [134, 256]. For example, low doses of SGI-110 (DNMT inhibitor) was found to drive ovarian CSCs towards a more differentiated phenotype and sensitise them to platinum treatment [125]. DOT1L inhibitor EPZ-5676 was also able to establish a chromatin state that enhanced the anti-tumor effects of cytarabine or daunorubicin in MLL-rearranged leukemia [255]. Moreover, pre-treatment with azacitidine was demonstrated to prime colon cancer cell lines to irinotecan therapy [257]. Indeed, various combinations have been tested in clinical trials with promising results on drug response and anti-tumor efficacy [258–261]. In addition to drug combination synergy, the method of delivery could also improve response to therapy. A recent paper by Li et al. showed that encapsulating decitabine and doxorubicin in nanoparticles was able to better target breast CSCs and inhibit tumor growth [262].

The use of immunotherapy in cancer has made significant progress over the past two decades, with several immunotherapy drugs being approved by the FDA for the treatment of cancer. These drugs function to overcome the mechanisms of immune tolerance that are employed by cancer cells to evade or limit the body’s immune response. These mechanisms include changes in antigen processing and presentation, creation of an immunosuppressive microenvironment, induction of T-cell death and activation of negative immune regulatory pathways [263]. One key receptor involved in the immunoinhibitory pathways is the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is expressed on the surface of immune cells and acts as an immune checkpoint. Studies have shown that targeting CTLA-4 receptor induced favourable responses in patients with advanced melanoma [264], and the FDA-approved CTLA-4 inhibitor, Ipilimumab, is now in clinical trials for prostate and lung cancers. Another immune checkpoint involved in tumor immune-resistance is the interaction between programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) [265]. Specific targeting of PD-1 and PD-L1 has been clinically shown to be very effective in treatment of metastatic cancers and melanomas [266, 267].

However, as most of these immunotherapy strategies are mainly targeted at bulk tumors, which contain more differentiated cells with “differentiation antigens” [268], CSCs (which have a different set of tumor antigens) would not be successfully eradicated. Hence, more effective targeting of the CSC population can be achieved via CSC-specific immunologic approaches, or by combining immunotherapy with epigenetic therapies that induce CSC differentiation and alter surface protein expression. The latter approach would likely improve the overall antitumor efficacy as both CSC and bulk tumor populations can be targeted simultaneously. For instance, the use of DNA hypomethylating agent (5-aza-2-deoxycytidine) in combination with anti-CTLA-4 monoclonal antibody in syngeneic transplantable murine models demonstrated significant reduction in tumor volumes as compared to single agent treatment alone [269]. The improved efficacy of this combination was attributed to the increased CD3+ T-cell infiltration in the combination cohort tumors and a sustained expression of cancer antigens and MHC proteins due to promoter demethylation. Furthermore, combinatorial drug treatment with immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1) and epigenetic modulators (5-azacytidine and Entinostat) showed remarkable eradication of CT26 colorectal tumors and 4 T1 mammary tumors in more than 80% of the tumor-bearing mice [270]. Importantly, 4 T1 tumor-bearing mice that were given combinatorial treatment did not develop metastases as compared to mice given single agent treatment. These findings demonstrate that epigenetic drugs in combination with immunotherapy can enhance the reversal of immune tolerance in cancer cells, including CSCs.

Another way in which cancer cells evade cytotoxic T-cells is by down-regulating human leukocyte antigen (HLA) to avoid tumor antigen presentation [134].
Hypermethylation of PLA promoters was frequently observed in gastric cancer and esophageal squamous cell cancers [271, 272]. Treatment with DNMT and HDAC inhibitors were found to be capable of reversing this hypermethylation and increasing PLA expression [272–275], thus priming these cells for immunotherapy. In addition, Li et al. showed that azacitidine treatment was able to enhance immunomodulatory pathways, such as antigen processing/presentation and interferon signaling, in breast, colorectal and ovarian cancers [276]. These preclinical data highlight the promising potential of combining epigenetic and immunotherapies in improving cancer treatment efficacy, which will be verified in several ongoing clinical trials.

Conclusion

Our understanding of cancer has changed over the last decade with the advances in sequencing technologies and the deciphering of the human genome. It is now clear to us that the tumor genome is complex and heterogeneous and that tumors do not arise from a single clone with a single tumor genome. We have discussed several important aspects and examples of how epigenetic deregulation may drive or promote tumorigenesis and metastasis by altering key transcriptional programs and signaling pathways, especially in CSCs. More importantly, we have provided several evidences that these epigenetic modifiers are targetable and many of these epigenetic modulating drugs have entered clinical trials, and some including azacitidine, decitabine, vorinostat, and the deciphering of the human genome. It is now clear to us that the tumor genome is complex and heterogeneous, and that tumors do not arise from a single clone with a single tumor genome. We believe that the success of these epigenetic therapeutic trials will provide a promising path to follow.

Abbreviations

ABC: ATP-binding cassette; ABCC2: ATP-binding cassette sub-family G member 2; ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; AML1-ETO: Acute myeloid leukemia protein 1 Eight twenty-one protein; APC: Adenomatous polyposis coli; ASCL1: Achaete-scute family BHLH transcription factor 1; BCC: Basal cell carcinoma; BCL2: B-cell lymphoma 2; BET: Bromodomain and extra-terminal; BMI1: B-lymphoma Mo-MLV insertion region 1 homolog; CK1: Casein kinase 1; CK19: Cytokeratin 19; CSC: Cancer stem cells; DACT3: Polycomb repressor complex 2 Dishevelled-binding region 1 homolog; CK1: Casein kinase 1; CK19: Cytokeratin 19; CSC: Cancer stem cells; DACT3: Polycomb repressor complex 2; DCR1: Dishevelled-related protein 1; DNMTs: DNA methyltransferases; DZNep: 3-deazaneplanocin A; ECM: Extracellular matrix; EED: Embryonic ectoderm development protein; EMT: Epithelial-to-mesenchymal transition; EpCAM: Epithelial cell adhesion molecule; ESCs: Embryonic stem cells; EZH2: Enhancer of zeste homolog 2; FDA: Flavin adenine dinucleotide; G9a/EED: Euchromatic histone lysine methyltransferase 1; EZH2: Enhancer of zeste homolog 2; FAD: Flavin adenine dinucleotide; GLP/EHMT1: Euchromatic histone lysine methyltransferase 1; GNPs: Granule neuron progenitors/precursors; GSK-3β: Glycogen synthase kinase 3 beta; H3K27: Histone H3 lysine 27; H3K36: Histone H3 lysine 36; H3K4: Histone H3 lysine 4; H3K79: Histone H3 lysine 79; H3K9: Histone H3 lysine 9; H4K8: Histone H4 lysine 20; HAT: Histone acetyltransferases; HCC: Hepatocellular carcinoma; HDAC: Histone deacetylase; Hh: Hedgehog; HKTMT: Histone lysine methyltransferase; HoxA9: Homeobox A9; ICC: Intrahepatic cholangiocarcinoma; Jmnc: Jumonji domain-containing (Jmnc); KDM: Histone lysine demethylase; Kif7: Kinesin family member 7; LDR5/6: Low density lipoprotein receptor-related protein 5/6; LSD: Lysine-specific demethylase; MDR1: Multidrug resistance protein 1; Meis1: Meis homeobox 1; miRNAs: Micro RNAs; MLL: Mixed lineage leukemia; MLL2: Mixed lineage leukemia protein 2; MRP1: Multidrug resistance-associated protein 1; NF-kB: Nuclear factor kappa b; NICD: Notch intracellular domain; NIDK1: Naked cuticle homolog 1; NMC: NUT midline carcinoma; NSCLC: non-small cell lung cancer; NSCs: Neural stem cells; OCT4: Octamer-binding transcription factor 4; PML-RARa: Promyelocytic leukemia protein retinoic acid receptor alpha; PTC1: Patched receptor; RBPJ: Recombination signal binding protein for immunoglobulin kappa J region; SAH: S-adenosylhomocysteine hydrolyase; SAM: S-adenosyl methionine; SFEP1: Secreted frizzled-related protein 1; Shh: Sonic hedgehog ligand; Sirt1: Sirtuin 1; SMO: Smoothened; SMRT: Nuclear receptor co-repressor 2; SNAIL: Snail family zinc finger 1; SP: Side population; STRAP: Serine-threonine kinase receptor-associated protein; SUFU: Suppressor of fused homolog; SUZ12: Suppressor of variegation 3–9 homolog 1; SUZ12: Suppressor of variation 3–9 homolog 2; Sux1: Suppressor of zeste 12 protein homolog; TCF/LEF: T-cell factor/lymphoid enhancer factor; TGF-β: Transforming growth factor-β; TNBC: Triple-negative breast cancer; TWIST1: Twist-related protein 1; UTx: Ubiquitously transcribed tetraspincpeptide repeat, X chromosome (UTX); WF-1: Wnt inhibitory factor 1; ZEB1: Zinc finger E-box-binding homeobox 1; ZEB2: Zinc finger E-box-binding homeobox 2

Acknowledgements

We apologize for not reviewing numerous original and pertinent articles due to space limitations and the scope of this review. We would also like to thank Mr. Wong Chun Xi (Mechanobiology Institute, Singapore) for his help in illustrating the figure in this manuscript.

Funding

The authors are supported by the National Research Foundation Cancer Science Institute of Singapore RCE Main Grant, Ministry of Education Academic Research Fund (MOE AcRF Tier 2 (MOE2015-T2–2-126, Seed Fund Grant T1–BSRG 2014–05). This work is funded by the NCS Yong Siew Yoon Research Grant through donations from the Yong Loo Lin Trust.

Availability of data and materials

Not applicable.

Authors’ Contributions

TBT, JIL and EKC were major contributors in the writing of the manuscript. TBT and EKC designed the manuscript. EKC revised and edited the manuscript. All authors read and approved the final manuscript.

Competing Interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Author details

1. Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. 2. Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 3. Centre for Translational Medicine, National University of Singapore, 14 Medical Drive 1#12-01, Singapore 117599, Singapore.

Received: 5 October 2016 Accepted: 19 January 2017

Published online: 01 February 2017

References

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–7.
3. Lapidot T, Sirard C, Virmoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature. 1994;376:645–8.
4. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5.

5. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dikiks PB. Identification of human brain tumour initiating cells. Nature. 2004;432:94–101.

6. Schatten T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345–9.

7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer stem cells. Proc Natl Acad Sci U S A. 2003;100:10062–7.

8. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68:4311–20.

9. Ma S, Chan KW, Hu L, Lee TK, Wo YJ, Ng IO, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542–56.

10. Collins AT, Berry PA, Hydie C, Stover MJ, Matlud NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.

11. Erano A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Diff. 2008;15:504–14.

12. Beier D, Hau P, Proeschold M, Lohmeyer A, Wischhusen J, Defeer PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. CD133(+) and CD133(−) glioblastoma-derived stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67:4010–5.

13. Kemper K, Spirk MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeltiš J, Pals ST, Mehnert H, Sassi G, Medema JP. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010;70:719–29.

14. Zhou F, Gui C, Ge Y, Chen H, Li Q, Yang Z, Wu G, Sun S, Chen K, Gu J, et al. Alpha2,3-Sialylation regulates the stability of stem cell marker CD133. J Biochem. 2010;148:273–80.

15. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136:1016–24.

16. Wilson GS, Hu Z, Duan W, Tian A, Wang XM, McLeod D, Lam V, George J, et al. Tobacco smoke induces polycomb-mediated repression of glioblastoma-stem cell markers. Proc Natl Acad Sci U S A. 2008;105:16706–11.

17. Chow BC, Fan LL, Chen X, Bishop JM. Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology. 2012;56:1549–59.

18. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 2017;77:11722–80.

19. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345–9.

20. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer stem cells. Proc Natl Acad Sci U S A. 2003;100:10062–7.

21. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929–35.

22. Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 2011;71:17722–80.

23. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007;16 Spec No 1:R25–37.

24. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92.

25. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Fishman RS, Xu H, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68:4311–20.

26. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5.

27. Spellman MR. Role of protein methylation in chromatin remodeling and transcriptional regulation. Oncogene. 2001;20:3014–20.

28. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693–705.

29. Wongtrakosongpute P. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries. World J Stem Cells. 2015;7:137–48.

30. Toh et al. Molecular Cancer (2017) 16:29
human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest. 2010;120:1013–14.

53. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;425:234–31.

54. Teglund S, Tolfgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta. 1805;2010:181–208.

55. Youssef KV, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achoury V, Sotkopoulou PA, Bianpain C. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2012;14:299–305.

56. Sellheyer K. Basal cell carcinoma: cell of origin, cancer stem cell hypothesis and stem cell markers. Br J Dermatol. 2011;164:696–711.

57. Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulou M, Schulte U, Machold R, Fishell G, Rowitch DH, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell. 2008;14:135–45.

58. Schuller U, Heine MA, Mo K, Ah AT, Dillon AK, Han YG, Huillard E, Sun T, Ligon AH, Qian Y, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form SH-induced medulloblastoma. Cancer Cell. 2008;14:123–34.

59. Biegel JA, Zhou JY, Riethmuller G, Weng X, Li X, Fischbach MA, Gehm-line and acquired mutations of IN1 in atypical teratoid and rhabdoid tumours. Cancer Res. 1999;59:74–9.

60. Sevenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O. Constitutional mutations of the HES5/NF1 gene predispose to a variety of cancers. Am J Hum Genet. 1999;65:1342–4.

61. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Auriol C, Delattre O. Truncating mutations of HES5/NF1 in aggressive paediatric cancer. Nature. 1998;394:203–6.

62. Canetelli G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, Ferretti E, Miele E, et al. Histone deacetylase and Cul3-RBX1 ubiquitin ligase interact regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol. 2010;12:1324–32.

63. Di Marcotullio L, Ferretti E, De Smaele E, Argenti B, Mincione C, Zazzeroni F, Gallo R, Maruilli N, Napoliello M, Mantero M, et al. RBX1 ubiquitin ligase interacts with Hedgehog signalling components and is deleted in human medulloblastoma. Proc Natl Acad S U A. 2004;101:10833–8.

64. Cui W, Wang LH, Wen YY, Song M, Li BL, Chen XL, Xu M, An SX, Zhao J, Lu YY, et al. Expression and regulation mechanisms of Sonic Hedgehog in breast cancer. Cancer Sci. 2010;101:927–33.

65. Wang LH, Choi YL, Hua XY, Shin YK, Song YJ, Youn SJ, Yun HY, Park SM, Kim WJ, Kim HJ, et al. Increased expression of sonic hedgehog and altered Hedgehog signalling and is deleted in human medulloblastoma. Proc Natl Acad S U A. 2008;105:14867–72.

66. Duan ZH, Wang HC, Zhao DM, Ji XX, Song M, Yang XJ, Cui W. Cooperatively transcriptional and epigenetic regulation of sonic hedgehog overexpression drives malignant potential of breast cancer. Cancer Sci. 2015;106:1084–91.

67. Anderson ER, Endahl L. Therapeutic modulation of Notch signalling—are we there yet? Nat Rev Drug Discov. 2014;13:357–78.

68. Kopan R. Notch signaling. Cold Spring Harb Perspect Biol. 2012;4.

69. Andersson ER, Sandberg R, Endahl L. Notch signaling: simplicity in design, versatility in function. Development. 2011;138:3593–612.

70. Munoz P, Iliou MS, Esteller M. Epigenetic alterations involved in cancer stem cell number and tumour progression. Curr Top Dev Biol. 2010;92:367–96.

71. Liu J, Sato C, Cerletti M, Wagers A. Notch signaling in the regulation of stem cell numbers in vitro and in vivo. Nature. 2006;442:823–6.

72. Lopez-Arrillaga E, Rodilla V, Pellegrinet G, Giuri J, Iglesias M, Roman AC, Gutara S, Gonzalez S, Munoz-Canoves P, Fernandez-Salgueiro P, et al. BRM regulates murine intestinal stem-cell proliferation and self-renewal downstream of Notch. Development. 2015;142:41–50.

73. Yuan X, Wu H, Han N, Xu H, Chu Q, Yu S, Chen Y, Wu K. Notch signalling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J Hematol Oncol. 2014;7:87.

74. Ichida JK, Tcw J, Williams LA, Carter AC, Shi Y, Moura MT, Ziller M, Singh S, Koziol MA, Amabile G, Bock C, et al. Notch inhibition allows oncogene-independent generation of iPSCs. Nat Chem Biol. 2014;10:632–9.

75. Zhou J, Li P, Lu F, Liu N, Dai J, Ye J, Qu X, Sun X, Ma D, Park J, Ji C. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol. 2013;6:3.
E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008; 283:14910–4.

100. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis. J Biol Chem. 2012;287:39594–66.

101. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epigenetics of cancer stem cells: Pathways and therapeutics. Cancer Res. 2011;71:13867–7.

102. Tzou WH, Li H, Van Neste L, Cai Y, Robert C, Rassoul FV, Shin JH, Harbom KM, Beaty T, Pappou E, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21:1430–46.

103. Shukla S, Meeran SM, Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Lee HH, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol. 2011;13:317–23.

104. Tellez CS, Juri DE, Do K, Bernauer MA, Thomas CL, Damiani LA, Tesseract M, Leng S, Belinsky SA. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 2011;71:13867–7.

105. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14:3629–32.

106. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Acquisition of epithelial-mesenchymal transition features in gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69:2400–8.

107. Shuda S, Meeran SM. Epigenetics of cancer stem cell pathways and therapeutics. Biochim Biophys Acta. 2014;1844:59–62.

108. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logidon CD, McConkey DJ, Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69:3828–38.

109. Wu CP, Calagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008;1:93–105.

110. Wang Z, Low X, Hou W, Abdullah LN, Toh TB, Moh Abd Rashid M, Ho D, Chow BK. Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells. ACS Nano. 2014;8:11511–23.

111. Cho S, Lu M, Heer R, Na HR, Schneider E, Miele L, Beck WT. Notch 1 regulates the expression of the multidrug resistance gene ABCB1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A. 2011;108:20778–83.

112. Kim B, Stephen SL, Hanby AM, Horgan K, Perry SL, Richardson J, Roundhill EA, Vallette EM, Vergheze ET, Williams BJ, et al. Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy. BMC Cancer. 2015;15:634.

113. To KK, Polgar O, Ljungberg B. Transient low doses of DNA-demethylating agents inhibit multidrug resistance in cancer cells: a review of recent patent applications. Pharm Pat Anal. 2012;1:75–80.

114. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed cell growth and apoptosis. Nature. 2000;408:377–81.

115. Sharma S, Kelly JK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31:273–84.

116. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–15.

117. Duan H, Heckman CA, Bowser LW. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in (14;18) lymphomas. Mol Cell Biol. 2005;25:1608–19.

118. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4:13–8.

119. Gelmetti V, Zhang J, Ferrallini M, Minucci S, Pellicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998;18:785–91.

120. Loo J, Su F, Chen D, Shiloh A, Wu Deoxycytidine of p53 modulates its effect on cell growth and apoptosis. Nature. 2000;408:377–81.

121. Duan H, Heckman CA, Bowser LW. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in (14;18) lymphomas. Mol Cell Biol. 2005;25:1608–19.

122. Federico M, Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol. 2011;2011:475641.

123. Joo YG, Gong XJ, Mishra A, Cui X, Baylin SB, Azad NS, Ahuja N. Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics. 2015;7:215–35.

124. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arndt KM, Ducic M. Phase IIb multicenter trial of vorinostat for patients with persistent or recurrent epithelial ovarian or primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 1992;3:399–403.

125. Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, Li Y, Nephew KP, Matei D. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 2014;74:4922–32.
Huang J, Dorsey J, Chuikov S, Perez-Burgos L, Zhang X, Jenuwein T, Reinberg Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, Fukuda M, Van Aller GS, Pappalardi MB, Ott HM, Diaz E, Brandt M, Schwartz BJ, Miller WH, Chen YT, Zhu F, Lin WR, Ying RB, Yang YP, Zeng LH. The novel EZH2
McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, Shi J, Wang E, Zuber J, Rappaport A, Taylor M, Johns C, Lowe SW, Vakoc CR.
Li Z, Wang Y, Qiu J, Li Q, Yuan C, Zhang W, Wang D, Ye J, Jiang H, Yang J, Wang X, Zhao H, Lv L, Bao L, Wang X, Han S. Prognostic Significance of
Toh One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.

One. 2008;3:e2037.
226. Schenk T, Chen WC, Gollmar S, Howell L, Jin L, Hebestreit K, Klein HG, Popescu AC, Burmeister M, Mills K, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivate the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18:605–11.

227. Maes T, Tripa I, Mascaro C, Ortega A, Estanda A, Valls N, Castro-Palomino J, Aijo LB, Guz P. Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia. J Clin Oncol. 2013;31:e13543.

228. Mohammadi H, Smitheman KN, Cusan M, Liu Y, Pappalardi M, Fedorowicz K, Toh et al. Molecular Cancer review. Expert Opin Ther Pat. 2014;24:185–99.

229. Mohammad H, Smitheman K, Cusan M, Liu Y, Pappalardi M, Federowicz K, Toh et al. LSD1 and the chemistry of histone demethylation. Curr Opin Chem Biol. 2011;17:561–8.

230. Spruszel A, Schulte JH, Wenker S, Nandisch K, Tur R, Pfajger TW, Koerner M, et al. Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia. 2012;26:2039–51.

231. Mohammad HP, Smitheman KN, Kartam CD, Soong D, Fedorowicz KE, Van Aller GS, Schneck JL, Carlin Y, Liu Y, Butticcio M, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC Cancer Cell. 2015;28:57–69.

232. Lan F, Baylis PE, Rinn JL, Whetstone JR, Wang JK, Chen S, Iwase S, Alpatov R, Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.

233. Lee MG, Villa R, Trojer P, Norman J, Yan KP, Reinberg D, Di Croce L, Shiekhattar R. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science. 2007;318:447–52.

234. Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.

235. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.

236. Lee MG, Villa R, Trojer P, Norman J, Yan KP, Reinberg D, Di Croce L, Shiekhattar R. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science. 2007;318:447–52.

237. Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.

238. Park BK, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.

239. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.

240. Delmore JE, Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.

241. Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, Delmore JE, Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.

242. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.

243. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.

244. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.

245. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenhaber B, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nat 2007;474:731–4.
immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366: 2443–54.

267. Blaher JM, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Oudjii K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.

268. Pan Q, Li Q, Liu S, Ning N, Zhang X, Xu Y, Chang AE, Wicha MS. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches. Stem Cells. 2015;33:2085–92.

269. Covre A, Coral S, Nicolay H, Parisi G, Fazio C, Colizzi F, Fratta E, Di Giacomo AM, Siglotti L, Natale PG, Maio M. Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. Oncoimmunology. 2015;4:e1019979.

270. Kim K, Skora AD, Li Z, Liu Q, Tam AI, Blosser RL, Diaz Jr LA, Papadopoulos N, Kindler KW, Vogelstein B, Zhou S. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A. 2014;111:11774–9.

271. Qifeng S, Bo C, Xingtao J, Chuanliang P, Xiaogang Z. Methylation of the HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens. 2010;75:30–9.

272. Kitamura H, Toitgoe T, Asanuma H, Homma I, Sato N, Tsukamoto T. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol. 2007;178:690–6.

273. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser N, Santanellio F, Tomasi TB. Activation of MHCI class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000;165:17017–24.

274. Mora-Garcia Mde L, Duenas-Gonzalez A, Hernandez-Montes J, De la Cruz-Navarrete VF, Rosales VH, Cantu D, et al. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med. 2006;455.

275. Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5:8897–98.

276. Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours–lessons from the past. Nat Rev Clin Oncol. 2013;10:256–66.

277. Silverman LR, Fenaux P, Mufti GJ, Santin V, Hestholl-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011;117:2697–702.

278. Griffiths EA, Choy G, Redkar S, Taverna P, Azad M, Karpof AR. SGI-110. DNA Methyltransferase Inhibitor Oncolytic. Drugs Future. 2013;38:535–43.

279. Issa JP, Roboz G, Rizzi D, Jabbour E, Stock W, O’Connell C, Yee K, Tiberis R, Griffiths EA, Walsh K, et al. Safety and tolerability of decitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase I study. Lancet Oncol. 2015;16:999–1010.

280. Fang F, Munck I, Tang J, Taverna P, Wang Y, Miller DF, Pilrose J, Choy G, Azad M, Pavczak KS, et al. The novel, small-molecule DNA methyltransferase inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res. 2015;21:4673–81.

281. Mackay HJ, Hirte H, Colgan T, Covens A, MacAlpine K, Gencic P, Wang L, Mason J, Pham PA, Tsao MS, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and microsatellite (MM) ovarian tumours. Eur J Cancer. 2010;46:1573–9.

282. Chu QJ, Nielsen TO, Alicindor T, Gupta A, Endo M, Goyatin A, Xu H, Verma S, Tozer R, Knowling M, et al. A phase II study of SGI-110, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas.NCIC-CTG IND 200dgag. Ann Oncol. 2015;26:973–81.

283. Eigl BJ, North S, Winkquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, et al. A phase II study of the HDAC inhibitor SB989 in patients with castration resistant prostate cancer; NCIC clinical trials group study IND195. Invest New Drugs. 2015;33:949–76.

284. Rambaldi A, Dellacasa CM, Finazzi G, Carobbo A, Ferrari ML, Guglielmelli P, Gattone S, Salmoiraghi S, Finazzi MC, Di Tollo S, et al. A pilot study of the Histone-Deacetylase Inhibitor Givinostat in patients with JAKeV2671F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150:446–55.

285. Mavartia T, Ninomiya I, Inokuchi M, Harada S, Hayashi H, Oyama K, Makino I, Nakawpaha H, Miyashita T, Tajima H, et al. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through JH70 acetylation. Int J Oncol. 2015;47:2073–81.

286. Tan J, Yang X, Zhaung L, Jiang X, Chen W, Lee PL, Karutik RU, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21:1050–63.

287. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R, Farrar WL. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibitors tumorigenicity and tumor progression in prostate cancer. Mol Cancer. 2011;10:40.

288. Bradley WD, Arora S, Busby J, Balubasbraniami S, Gelhing VS, Naveschuk CG, Vasswani RG, Yuan CC, Hatton C, Zhao F, et al. EZH2 inhibitor efficacy in non-Hodgkin’s lymphoma does not require suppression of H3K27 monomethylation. Chem Biol. 2014;21:1463–75.

289. Krudener I, Chung CW, Cheng Z, Liddle J, Che K, Ibertey G, Bantscheff M, Bounta R, Bridges A, Daliio H, et al. Selective jumonn H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012;489:404–8.

290. Merten JZ, Conery AR, Bryant BM, Sandy P, Balubasbraniami S, Mele DA, Bergeron L, Sims 3rd RJ. Targeting MYC dependence in cancer by inhibiting BET bromodomain. Proc Natl Acad Sci U S A. 2011;108:16669–74.

291. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, et al. Discovery and characterization of enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24:777–90.

292. Dawson MA, Pinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WJ, Scung CH, Chong CW, Hopf C, Savitski MM, et al. Inhibition of BET recruitment to chromatin as an effective strategy for MLL-fusion leukaemia. Nature. 2014;517:857–59.

293. Long J, Li B, Rodriguez-Blanco J, Pastori C, Volmar CH, Capobianco AM, Sigalotti L, Natali PG, Maio M. Antitumor activity of epigenetic small-molecule DNA methyltransferase inhibitor (CPI-0610) of the Bromodomain and Extra-terminal (BET) Family as a Candidate for Human Clinical Trials. J Med Chem. 2016;59:1310–39.